HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that Excellus BlueCross BlueShield will continue to promote generic medication use through pharmacy programs and public education efforts. According to the new report entitled Blue Profiler: New York--Excellus BlueCross BlueShield, in 2007 the Blue Plan saw prescription drug costs increase 15 percent, with federal employee prescription costs tripling from 2006 to 2007. To curb these rising prescription costs, Excellus has utilized proprietary research along with public relations campaigns to highlight the cost savings of generic medication use over brand name drugs.

"Generic medication promotion will certainly help Excellus manage its pharmacy spend moving forward," stated Chris Lewis, market analyst at HealthLeaders-InterStudy and author of the report. "Excellus has used research and health trend tracking across its region as one way to differentiate itself from its competitors. In fact, results from an Excellus-initiated study demonstrated that switching to generic medications saved Upstate New Yorkers $227 million in 2007."

The report finds that generic medication use is encouraged through the Blue Plan's Generic Trial program, which provides patients with a free 30-day supply of medication when the prescription is first filled. Additionally, the Generic Advantage program requires a member choosing a brand name over the generic equivalent to pay the generic copay, plus the difference between the pharmacy's charge for the brand drug and its price for the generic.

Lewis continued, "Excellus' public education and pharmacy programs have helped generate a 60 percent generic fill rate across Upstate New York, up from 53 percent in 2005."

Blue Profiler: New York--Excellus BlueCross BlueShield is one of 15 Blue Profiler reports for 2008 on the nation's largest nonprofit Blue Cross Blue Shield plans, which together insure more than 50 million people.

About Blue Profiler

Blue Profiler offers the most comprehensive analysis of the nonprofit Blue Cross Blue Shield plans. Each report focuses on an individual nonprofit Blue plan and includes valuable analysis that will allow companies to more effectively partner with these dominant organizations. Each report includes information on:

  -- Competitive analysis   -- Enrollment trends   -- Company-wide financials   -- HMO financials   -- Consumer-driven products   -- Medicare strategy   -- Pharmacy   -- Disease Management    About HealthLeaders-InterStudy 

HealthLeaders-InterStudy, a company of Decision Resources, Inc., is the authoritative source for managed care data and analysis. For more information, please visit www.HealthLeaders-InterStudy.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources,   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: HealthLeaders-InterStudy

CONTACT: Elizabeth Marshall of Decision Resources for
HealthLeaders-InterStudy, +1-781-296-2563, emarshall@dresources.com

Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed

View Now